An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...

Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025. Data from the KEYNOTE-905 trial (NCT03924895) showed that perioperative enfortumab vedotin ...

The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure. In this video, Sean P. Collins, MD, PhD, a radiation oncologist at Tampa General Hospital in Tampa ...

Disitamab vedotin plus toripalimab nearly doubled progression-free and overall survival compared to chemotherapy in HER2-expressing la/mUC patients. The combination therapy showed a 64% reduction in ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

Panelists discuss how IsoPSA improves diagnostic accuracy by targeting PSA protein structure, offering clearer insights for patient selection than concentration-based testing. Panelists discuss how ...

Discover innovative approaches to treating premature ejaculation with insights from leading experts in sexual health and urology. At the 2025 Sexual Medicine Society of North America meeting in ...

Panelists discuss how structure-based biomarkers such as IsoPSA improve risk stratification by distinguishing aggressive disease from indolent cases more effectively than PSA level alone. Panelists ...

This segment outlines how immune checkpoint inhibitors have become essential in bladder cancer management, examining their roles across treatment lines and the current standards of care. This program ...

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer. 3. Terence Friedlander, MD, provides ...